linjc16/ctgov huggingface dataset:
Influence of Dogs on Learning in Children

Study Overview
=================
Brief Summary
-----------------
In a randomised controlled cross-over study, the influence of interacting with a dog on children's learning performance is investigated.

Official Title
-----------------
Influence of Interacting With Dogs on Learning in Children

Conditions
-----------------
Learning, Human-animal Interaction

Intervention / Treatment
-----------------
* Other: Human-dog interaction
* Other: Stuffed toy dog


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy 7 - 14 years old willingness to participate Exclusion Criteria: medical or psychiatric diagnosis medication allergia (dogs) phobia (dogs)

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: starting with dog<br>Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog. | Other: Human-dog interaction<br>* The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.<br>Other: Stuffed toy dog<br>* The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.<br>|
| Experimental: starting with control<br>Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog. | Other: Human-dog interaction<br>* The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.<br>Other: Stuffed toy dog<br>* The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VLMT (Verbaler Lern- und Merkfähigkeitstest) | Number of remembered items within the test | 20 Minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Digit Span (from HAWIK-IV) | Number of remembered items (auditively presented numbers) | 5 Minutes | 
| motoric task (from Kaufman Assessment Battery for Children, dt. Version (K-ABC)) | Number of remembered items (visually presented gestures) that can be reproduced. | 5 Minutes | 
| Heart rate/heart rate variability |  | 60 Minutes |
Tritanium® Study in Japan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate early fixation and stability of the Tritanium cup. It is expected that the Tritanium® cup will be equal to or better than conventional cementless cups in early fixation/stability and meet the expectations of Japanese surgeons.

Official Title
-----------------
The Verification Study on the Early Fixation/ Stability of Tritanium Cup

Conditions
-----------------
Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis of the Femoral Head

Intervention / Treatment
-----------------
* Device: Tritanium® cup


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is a candidate for a primary Total Hip Arthroplasty (THA). Patient who has diagnosis of secondary osteoarthritis, avascular necrosis and rheumatoid arthritis. Patient whose age is 20 or over. Patient who signed an Institutional Review Board (IRB)-approved, study specific Informed Patient Consent Form. Patient who is willing and able to comply with postoperative scheduled evaluations. Exclusion Criteria: Patient who has a bacterial infectious disease or has a high risk of a bacterial infection. Patient who requires revision surgery of a previously implanted total hip arthroplasty. Patient who is morbidly obese, defined as having a Body Mass Index (BMI) > 40. Patient who is or may be pregnant female. Patient who has neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device. Patient with diagnosed systemic disease (i.e. Paget's disease, renal osteodystrophy), which limits ability to evaluate the safety and efficacy of the device. Patient who is immunologically suppressed or receiving chronic steroids, which limits ability to evaluate the safety and efficacy of the device. Patients who is judged ineligible with specific reason by primary doctor.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tritanium® cup<br> | Device: Tritanium® cup<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in implantation position(angle) of the cup |  | Baseline, intraoperative, 3 months, 6 months and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Japanese Orthopaedic Association (JOA) score |  | Baseline, 3 months, 6months and 12 months | 
| Change in Quality of Life as assessed by Euro QOL 5 Dimension (EQ-5D) |  | Pre-operation, 3 months, 6months and 12 months |
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

Study Overview
=================
Brief Summary
-----------------
Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors. There are gene mutations that increase the risk for the disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if there is a difference between the metabolic brain function of Parkinson patients that carry one of the two mutations to Parkinson patients with no known mutation. Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes, Parkinson patients with no known mutation and healthy volunteers as a control group. The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv Sourasky Medical Center Nuclear Medicine Institute. The examination results will be given to the participants by a doctor from the neurology department.

Official Title
-----------------
I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed Parkinson patients with known genetic characteristics Exclusion Criteria: patients unable to understand and sign an informed consent minors patients in medical condition that does not allow them to stay still during the examination

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| LRRK2 mutation<br>Parkinson patients that carry mutation on LRRK2 gene | |
| GBA mutation<br>Parkinson patients that carry mutation on GBA gene | |
| no mutation<br>Parkinson patients that don't carry mutation on LRRK2 or GBA genes | |
| healthy<br>Healthy volunteers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
parkinson, fdg pet-ct, i123 dat scan, LRRK2, GBA, parkinson patients with known genetic characteristic
Effect of Weight Loss Diet and Pumpkin Seed Flour Consumption on Obese Women

Study Overview
=================
Brief Summary
-----------------
This study aimed to evaluate the effect of weight loss diet combined with pumpkin seed flour consumption on diet improvement, weight loss, and glucose and cholesterol reduction in obese.

Official Title
-----------------
Effect of Hypoenergetic Diet Combined With Pumpkin Seed Flour Consumption on Obese Women

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Dietary Supplement: pumpkin seed flour
* Dietary Supplement: Placebo (cassava flavored flour)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age from 20 to 59 years old. body mass index above 30 kg/m2 Exclusion Criteria: diabetic loss weight before the research consumption of vitamins or dietary supplement. pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: pumpkin seed flour<br>The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks | Dietary Supplement: pumpkin seed flour<br>* The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks<br>|
| Placebo Comparator: Cassava flavored flour<br>The placebo group (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks. | Dietary Supplement: Placebo (cassava flavored flour)<br>* The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anthropometric measures | body weight (kg), body mass index (kg/m2), waist circumference (cm), neck circumference | Change from Baseline at 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood lipids | total Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides (mg/dl) | Change from baseline at 12 weeks | 
| Blood glucose | glucose (mg/dL) | Change from baseline at 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, cardiovascular risk factors, pumpkin seed, diet quality
Pathogen Detection and Community Acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
Study to compare the number of community-acquired pneumonia (CAP) pathogens detected using current diagnostic tests to the number detected using the BioFire Diagnostics investigational polymerase chain reaction (PCR) platform.

Detailed Description
-----------------
Patients diagnosed in the emergency department with CAP that requires hospitalization provide a sputum sample for culture and sensitivity testing, urine for detection of S. pneumonia and L. pneumophila, an anterior nasal swab for S. aureus PCR, a nasopharyngeal swab for S. pneumonia PCR and the FilmArray LRTI v.2.0 IUO Panel, and blood for procalcitonin testing and, in cases in which the patient is suffering rigors and hypotension, cultures. As part of this study, sputum or sputum equivalent will be acquired for testing using the FilmArray LRTI v.2.0 IUO Panel.

Official Title
-----------------
Projected Influence of Enhanced Pathogen Detection on the Clinical Management of Community-Acquired Pneumonia

Conditions
-----------------
Community Acquired Pneumonia

Intervention / Treatment
-----------------
* Other: FilmArray LRTI v.2.0 IUO Panel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency Department physician diagnosis of CAP requiring hospitalization Exclusion Criteria: Inability to obtain sputum or sputum equivalent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FilmArray LRTI v.2.0 IUO Panel<br>Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing. | Other: FilmArray LRTI v.2.0 IUO Panel<br>* Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathogen Detection | Compare the number of CAP pathogens detected using current diagnostic bundle to the number detected using the FilmArray LRTI v.2.0 IUO Panel. | 5 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment Influence | Determine the number of cases in which the FilmArray LRTI v.2.0 IUO Panel could allow for a switch from empiric to specific antimicrobial therapy if the results had been known by the healthcare provider. | 5 Days | 
| Nasopharyngeal swabs compared to sputum | Compare the number of pathogens detected using an approved PCR panel using nasopharyngeal swabs to the number detected using the FilmArray LRTI v.2.0 IUO Panel. | 5 Days |
Respiratory Problems and Caries in Children With Bruxism

Study Overview
=================
Brief Summary
-----------------
The aim of the present study are to determine whether there is an association between respiratory problems and dental caries in children who exhibit the habit of bruxism.

Detailed Description
-----------------
Objectives: The aim of the present study was to determine whether there is an association between respiratory problems and dental caries in children who exhibit the habit of bruxism. Method: Patient histories were taken and clinical exams were performed on 90 children for selection and allocation to one of two groups. For the determination of bruxism, a questionnaire was administered to parents/guardians and an oral clinical exam was performed based on the criteria of the American Academy of Sleep Medicine. Thirty-three male and female children between four and seven years of age participated in the present study - 14 children with bruxism and 19 children without bruxism. The data were statistically analyzed using the chi-square test, with level of significance set at 5% (p < 0.05).

Official Title
-----------------
Association Between Respiratory Problem and Dental Caries in Children With Bruxism

Conditions
-----------------
Bruxism, Dental Caries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with either the complete primary or mixed dentition who were not in dental treatment Exclusion Criteria: Children in dental treatment

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children with bruxism<br>14 children with bruxism | |
| children without bruxism<br>19 children without bruxism | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bruxism, children, oral breathing, dental caries
Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)

Study Overview
=================
Brief Summary
-----------------
Triclabendazole is a benzimidazole compound used as a systemic antihelmintic in veterinary practice. Triclabendazole is considered to be a second-line drug for parasites and is used when other preferred agents cannot be used because they are ineffective or because adverse reactions limit their use. Although Triclabendazole is widely used in developing countries for the treatment of parasites it is not approved by the FDA for this treatment in the US. It is currently being distributed in the US through a special arrangement with the FDA and the manufacturer on an individual patient approval basis. This arrangement requires that a single patient Investigational New Drug (IND) be obtained from FDA for each patient requiring Triclabendazole. Upon approval by FDA, the manufacturer (Novartis) will ship the drug directly to the prescribing physician.

Official Title
-----------------
Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)

Conditions
-----------------
Parasitic Disease

Intervention / Treatment
-----------------
* Drug: Triclabendazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of parasites whose resistance pattern has indicated resistance to first line agents and sensitivity to Triclabendazole or in whom an additional drug needs to be added to their regimen because of inadequate response to existing therapy. Patients with a parasite that is sensitive to Triclabendazole and who have experienced an allergic or adverse reaction to other agents that prevent their use. Patients with parasitic disease that has responded to treatment with first line drugs but who experienced allergic or adverse reactions to these agents that has prevented their continued use or who have experienced a relapse in their disease that necessitates the addition, or substitution, of second-line agents Patients who do not qualify for a study using Triclabendazole or for whom a study does not exist and thus the patient would not otherwise have access to the drug Exclusion Criteria: Anyone whose parasitic disease can be adequately treated by other available medications. Anyone who is allergic or who has had a severe adverse reaction to Triclabendazole in the past. Pregnant Women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Neurofibromatosis-associated Tumor Biobank

Study Overview
=================
Brief Summary
-----------------
Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research

Detailed Description
-----------------
Samples of blood and other stored material such as slides,frozen tissues or leftover diagnostic material. Questionnaire information, including health history, growth and development, physical activity and family medical history information. If patients have been diagnosed with a neurofibromatosis-associated tumor or another condition the investigator is interested in， the investigator will ask the patient to release medical record information relating to diagnosis and treatment of neurofibromatosis-associated tumor, other cancers, blood disorders, and similar conditions.

Official Title
-----------------
Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction

Conditions
-----------------
Neurofibromatoses

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Proband Inclusion criteria: A diagnosis or suspected diagnosis of neurofibromatosis-associated tumor Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with neurofibromatosis-associated tumor Exclusion Criteria: non-asian
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor | To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bone tumor